摘要
目的 探讨丁苯酞联合阿加曲班治疗进展型脑梗死的临床疗效、安全性及对患者远期复发风险的影响.方法 选取2017年8月-2020年8月在天津市静海区医院治疗进展型脑梗死的患者98例作为研究对象,按照单双号均分成观察组和对照组,每组49例患者.对照组常规治疗基础上给予丁苯酞软胶囊,而观察组同时给予丁苯酞和阿加曲班.观察比较两组患者临床疗效、安全性有无差异,同时随访12个月,观察两组患者再发脑梗死风险有无差异.结果 观察组总有效率为91.8%,对照组总有效率为71.4%,两组进展型脑梗死患者的临床疗效差异具有统计学意义(P<0.05);观察组不良反应发生率为14.3%,对照组不良反应发生率为12.2%,两组进展型脑梗死患者的不良反应发生率差异无统计学意义(P>0.05).两组治疗后随访12个月,对照组再发脑梗死12例,而观察组再发脑梗死4例,观察组12个月内再发脑梗死风险明显低于对照组且有统计学差异(HR=0.29,95%CI:0.12-0.86,P<0.05).结论 丁苯酞联合阿加曲班治疗进展型脑梗死疗效确切,未增加不良反应发生率,同时可降低12个月内再发脑梗死风险.
Objective To investigate the clinical efficacy,safety and long-term recurrence risk of butylphthalide combined with argatroban in the treatment of progressive cerebral infarction.Methods 98 patients with progressive cerebral infarction treated in Jinghai District Hospital of Tianjin from August 2017 to August 2020 were selected as the research object.They were divided into observation group and control group according to single and double numbers,with 49 patients in each group.The control group was given butylphthalide soft capsule on the basis of routine treatment,while the observation group was given butylphthalide and argatroban at the same time.The clinical efficacy and safety of the two groups were observed and compared.At the same time,the patients were followed up for 12 months to observe the risk of recurrent cerebral infarction between the two groups.Results The effective treatment rate was 91.8% in the observation group and 71.4%in the control group.There was significant difference in clinical efficacy between the two groups(P<0.05);the incidence of adverse reactions was 14.3%in the observation group and 12.2%in the control group.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The two groups were followed up for 12 months after treatment.There were 12 cases of recurrent cerebral infarction in the control group and 4 cases in the observation group.The risk of recurrent cerebral infarction in the observation group was significantly lower than that in the control group within 12 months(HR=0.29,95%CI:0.12-0.86,P<0.05).Conelusion Butylphthalide combined with argatroban is effective in the treatment of progressive cerebral infarction,does not increase the incidence of adverse reactions,and can reduce the risk of recurrent cerebral infarction within 12 months.
作者
吴金彦
Wu Jinyan(Department of Neurology,Jinghai district hospital,Tianjin 301600)
出处
《首都食品与医药》
2022年第14期64-66,共3页
Capital Food Medicine
关键词
丁苯酞
阿加曲班
脑梗死
预后
Butylphthalide
Agatraban
Cerebral infarction
Prognosis
